Masaaki Ito1, Takaki Hiwasa1,2, Satoshi Yajima3, Takashi Suzuki3, Yoko Oshima3, Tatsuki Nanami3, Makoto Sumazaki3, Fumiaki Shiratori3, Shu-Yang Li2, Yasuo Iwadate2, Kazuo Sugimoto4, Masahiro Mori4, Satoshi Kuwabara4, Hirotaka Takizawa5, Hideaki Shimada6,7. 1. Department of Gastroenterological Surgery and Clinical Oncology, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan. 2. Department of Neurological Surgery, Chiba University Graduate School of Medicine, Chiba, 260-8670, Japan. 3. Department of Gastroenterological Surgery, Toho University School of Medicine, Tokyo, Japan. 4. Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan. 5. Port Square Kashiwado Clinic, Kashiwado Memorial Foundation, Chiba, 260-0025, Japan. 6. Department of Gastroenterological Surgery and Clinical Oncology, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan. hideaki.shimada@med.toho-u.ac.jp. 7. Department of Gastroenterological Surgery, Toho University School of Medicine, Tokyo, Japan. hideaki.shimada@med.toho-u.ac.jp.
Abstract
BACKGROUND: Cofilin (CFL1, actin-binding protein) and β-actin (ACTB) are key molecules in the polymerization and depolymerization of actin microfilaments. The levels of these antibodies were analyzed, and the clinicopathological significance in patients with esophageal carcinoma were evaluated. METHODS: The levels of anti-CFL1 and anti-ACTB antibodies were analyzed in serum samples of patients with esophageal carcinoma and of healthy donors. Eighty-seven cases underwent radical surgery and the clinicopathological characteristics and prognosis was examined. RESULTS: Serum anti-CFL1 antibody (s-CFL1-Ab) levels and anti-ACTB antibody (s-ACTB-Ab) levels were significantly higher in patients with esophageal carcinoma than in healthy donors. Following the receiver operating characteristic curve analysis between healthy donors and esophageal carcinoma, the sensitivity and specificity for serum anti-CFL1 antibody (s-CFL1-Ab) were 53.3% and 68.8%. The sensitivity and specificity for serum anti-ACTB antibody (s-ACTB-Ab) were 54.9% and 67.7%, respectively. Univariate and multivariate analysis showed that s-CFL1-Ab and s-ACTB-Ab levels were not associated with sex, age, tumor depth, lymph node metastasis, or anti-p53-antibody levels. s-ACTB-Ab levels but not s-CFL1-Ab levels significantly correlated with squamous cell carcinoma antigen. Neither s-CFL1-Ab nor s-ACTB-Ab levels alone were obviously related to overall survival. However, patients with low s-CFL1-Ab levels and high s-ACTB-Ab levels exhibited significantly more unfavorable prognoses than those with high s-CFL1-Ab and low s-ACTB-Ab levels. CONCLUSIONS: Serum levels of anti-CFL1 and anti-ACTB antibodies were significantly higher in patients with esophageal carcinoma than in healthy donors. A combination of low anti-CFL1 and high anti-ACTB antibodies is a poor prognostic factor in esophageal carcinoma.
BACKGROUND: Cofilin (CFL1, actin-binding protein) and β-actin (ACTB) are key molecules in the polymerization and depolymerization of actin microfilaments. The levels of these antibodies were analyzed, and the clinicopathological significance in patients with esophageal carcinoma were evaluated. METHODS: The levels of anti-CFL1 and anti-ACTB antibodies were analyzed in serum samples of patients with esophageal carcinoma and of healthy donors. Eighty-seven cases underwent radical surgery and the clinicopathological characteristics and prognosis was examined. RESULTS: Serum anti-CFL1 antibody (s-CFL1-Ab) levels and anti-ACTB antibody (s-ACTB-Ab) levels were significantly higher in patients with esophageal carcinoma than in healthy donors. Following the receiver operating characteristic curve analysis between healthy donors and esophageal carcinoma, the sensitivity and specificity for serum anti-CFL1 antibody (s-CFL1-Ab) were 53.3% and 68.8%. The sensitivity and specificity for serum anti-ACTB antibody (s-ACTB-Ab) were 54.9% and 67.7%, respectively. Univariate and multivariate analysis showed that s-CFL1-Ab and s-ACTB-Ab levels were not associated with sex, age, tumor depth, lymph node metastasis, or anti-p53-antibody levels. s-ACTB-Ab levels but not s-CFL1-Ab levels significantly correlated with squamous cell carcinoma antigen. Neither s-CFL1-Ab nor s-ACTB-Ab levels alone were obviously related to overall survival. However, patients with low s-CFL1-Ab levels and high s-ACTB-Ab levels exhibited significantly more unfavorable prognoses than those with high s-CFL1-Ab and low s-ACTB-Ab levels. CONCLUSIONS: Serum levels of anti-CFL1 and anti-ACTB antibodies were significantly higher in patients with esophageal carcinoma than in healthy donors. A combination of low anti-CFL1 and high anti-ACTB antibodies is a poor prognostic factor in esophageal carcinoma.
Authors: Jose Javier Bravo-Cordero; Marco A O Magalhaes; Robert J Eddy; Louis Hodgson; John Condeelis Journal: Nat Rev Mol Cell Biol Date: 2013-06-19 Impact factor: 94.444
Authors: U Sahin; O Türeci; H Schmitt; B Cochlovius; T Johannes; R Schmits; F Stenner; G Luo; I Schobert; M Pfreundschuh Journal: Proc Natl Acad Sci U S A Date: 1995-12-05 Impact factor: 11.205